These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29276815)

  • 41. Development of a Ligand Screening Tool Using Full-Length Human Peroxisome Proliferator-Activated Receptor-Expressing Cell Lines to Ameliorate Metabolic Syndrome.
    Tachibana K; Ishimoto K; Takahashi R; Kadono H; Awaji T; Yuzuriha T; Tanaka T; Hamakubo T; Sakai J; Kodama T; Aoki S; Doi T
    Chem Pharm Bull (Tokyo); 2019; 67(3):199-202. PubMed ID: 30827999
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons.
    Cimini A; Benedetti E; Cristiano L; Sebastiani P; D'Amico MA; D'Angelo B; Di Loreto S
    Neuroscience; 2005; 130(2):325-37. PubMed ID: 15664689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peroxisome-proliferator-activated receptors and the control of levels of prostaglandin-endoperoxide synthase 2 by arachidonic acid in the bovine uterus.
    Sheldrick EL; Derecka K; Marshall E; Chin EC; Hodges L; Wathes DC; Abayasekara DR; Flint AP
    Biochem J; 2007 Aug; 406(1):175-83. PubMed ID: 17516915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: relationship between absolute configuration and subtype selectivity.
    Motoshima K; Ishikawa M; Hashimoto Y; Sugita K
    Bioorg Med Chem; 2011 May; 19(10):3156-72. PubMed ID: 21514830
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
    Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
    Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An update about the crucial role of stereochemistry on the effects of Peroxisome Proliferator-Activated Receptor ligands.
    Laghezza A; Piemontese L; Tortorella P; Loiodice F
    Eur J Med Chem; 2019 Aug; 176():326-342. PubMed ID: 31112893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
    Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
    Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Virtual screening of antitumour phytochemical against peroxisome proliferators activated receptor proteins PPARs.
    Riaz S; Ahmed M; Hasnain S
    Pak J Pharm Sci; 2020 Jan; 33(1(Supplementary)):379-383. PubMed ID: 32122871
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening.
    Markt P; Petersen RK; Flindt EN; Kristiansen K; Kirchmair J; Spitzer G; Distinto S; Schuster D; Wolber G; Laggner C; Langer T
    J Med Chem; 2008 Oct; 51(20):6303-17. PubMed ID: 18821746
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structure-activity relationship analyses of glycyrrhetinic acid derivatives as anticancer agents.
    Lallemand B; Gelbcke M; Dubois J; Prévost M; Jabin I; Kiss R
    Mini Rev Med Chem; 2011 Sep; 11(10):881-7. PubMed ID: 21762107
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antitumor efficacy of two novel non-thiazolidinedione compounds as peroxisome proliferator-activated receptor-gamma agonists in human osteosarcoma cells in vitro.
    Fu L; Xiong X; Wang L; Gao X; Ye Y; Jia J; Hu H; Li L; Shen J; Mei C
    Chemotherapy; 2009; 55(6):468-76. PubMed ID: 19996593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bladder-cancer-associated mutations in
    Halstead AM; Kapadia CD; Bolzenius J; Chu CE; Schriefer A; Wartman LD; Bowman GR; Arora VK
    Elife; 2017 Nov; 6():. PubMed ID: 29143738
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Peroxisome proliferator activated receptors (PPAR) and insulin sensitivity: experimental studies].
    Haluzík MM; Haluzík M
    Cesk Fysiol; 2006; 55(4):163-8. PubMed ID: 17685022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PPARs are mediators of anti-cancer properties of superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with conjugated linoleic acid.
    Ricci M; Miola M; Multari C; Borroni E; Canuto RA; Congiusta N; Vernè E; Follenzi A; Muzio G
    Chem Biol Interact; 2018 Aug; 292():9-14. PubMed ID: 29986832
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of polycyclic aromatic hydrocarbons in the activation of early growth response-1 and peroxisome proliferator activated receptors.
    Kim JH; Yamaguchi K; Lee SH; Tithof PK; Sayler GS; Yoon JH; Baek SJ
    Toxicol Sci; 2005 May; 85(1):585-93. PubMed ID: 15716483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: design, synthesis, and effects on cardiomyocyte differentiation.
    Wei ZL; Petukhov PA; Bizik F; Teixeira JC; Mercola M; Volpe EA; Glazer RI; Willson TM; Kozikowski AP
    J Am Chem Soc; 2004 Dec; 126(51):16714-5. PubMed ID: 15612696
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.
    Aleshin S; Strokin M; Sergeeva M; Reiser G
    Neurochem Int; 2013 Oct; 63(4):322-30. PubMed ID: 23811400
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PPAR: a mediator of peroxisome proliferator action.
    Green S
    Mutat Res; 1995 Dec; 333(1-2):101-9. PubMed ID: 8538617
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PPAR activation and decreased proliferation in oral carcinoma cells with 4-HPR.
    Harris G; Ghazallah RA; Nascene D; Wuertz B; Ondrey FG
    Otolaryngol Head Neck Surg; 2005 Nov; 133(5):695-701. PubMed ID: 16274795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.